Computational approaches for predicting the biological effect of p53 missense mutations: a comparison of three sequence analysis based methods

被引:274
作者
Mathe, E
Olivier, M
Kato, S
Ishioka, C
Hainaut, P
Tavtigian, SV
机构
[1] WHO, Int Agcy Res Canc, Genet Susceptibil Grp, F-69372 Lyon 08, France
[2] George Mason Univ, Dept Bioinformat & Computat Biol, Manassas, VA USA
[3] Tohoku Univ, Inst Dev Aging & Canc, Dept Clin Oncol, Sendai, Miyagi 9808575, Japan
关键词
D O I
10.1093/nar/gkj518
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Prediction of the biological effect of missense substitutions has become important because they are often observed in known or candidate disease susceptibility genes. In this paper, we carried out a 3-step analysis of 1514 missense substitutions in the DNA-binding domain (DBD) of TP53, the most frequently mutated gene in human cancers. First, we calculated two types of conservation scores based on a TP53 multiple sequence alignment (MSA) for each substitution: (i) Grantham Variation (GV), which measures the degree of biochemical variation among amino acids found at a given position in the MSA; (ii) Grantham Deviation (GD), which reflects the 'biochemical distance' of the mutant amino acid from the observed amino acid at a particular position (given by GV). Second, we used a method that combines GV and GD scores, Align-GVGD, to predict the transactivation activity of each missense substitution. We compared our predictions against experimentally measured transactivation activity (yeast assays) to evaluate their accuracy. Finally, the prediction results were compared with those obtained by the program Sorting Intolerant from Tolerant (SIFT) and Dayhoff's classification. Our predictions yielded high prediction accuracy for mutants showing a loss of transactivation (similar to 88% specificity) with lower prediction accuracy for mutants with transactivation similar to that of the wild-type (67.9 to 71.2% sensitivity). Align-GVGD results were comparable to SIFT (88.3 to 90.6% and 67.4 to 70.3% specificity and sensitivity, respectively) and outperformed Dayhoff's classification (80 and 40.9% specificity and sensitivity, respectively). These results further demonstrate the utility of the Align-GVGD method, which was previously applied to BRCA1. Align-GVGD is available online at http://agvgd.iarc.fr.
引用
收藏
页码:1317 / 1325
页数:9
相关论文
共 32 条
  • [1] [Anonymous], 1978, ATLAS PROTEIN SEQ ST
  • [2] The Protein Data Bank
    Berman, HM
    Westbrook, J
    Feng, Z
    Gilliland, G
    Bhat, TN
    Weissig, H
    Shindyalov, IN
    Bourne, PE
    [J]. NUCLEIC ACIDS RESEARCH, 2000, 28 (01) : 235 - 242
  • [3] Cystic fibrosis: A worldwide analysis of CFTR mutations - Correlation with incidence data and application to screening
    Bobadilla, JL
    Macek, M
    Fine, JP
    Farrell, PM
    [J]. HUMAN MUTATION, 2002, 19 (06) : 575 - 606
  • [4] Caron De Fromentel Claude, 1992, Genes Chromosomes and Cancer, V4, P1
  • [5] CRYSTAL-STRUCTURE OF A P53 TUMOR-SUPPRESSOR DNA COMPLEX - UNDERSTANDING TUMORIGENIC MUTATIONS
    CHO, YJ
    GORINA, S
    JEFFREY, PD
    PAVLETICH, NP
    [J]. SCIENCE, 1994, 265 (5170) : 346 - 355
  • [6] The human gene mutation database
    Cooper, DN
    Ball, EV
    Krawczak, M
    [J]. NUCLEIC ACIDS RESEARCH, 1998, 26 (01) : 285 - 287
  • [7] TRITON: graphic software for rational engineering of enzymes
    Damborsky, J
    Prokop, M
    Koca, J
    [J]. TRENDS IN BIOCHEMICAL SCIENCES, 2001, 26 (01) : 71 - 73
  • [8] Characterization of disease-associated single amino acid polymorphisms in terms of sequence and structure properties
    Ferrer-Costa, C
    Orozco, M
    de la Cruz, X
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 2002, 315 (04) : 771 - 786
  • [9] AMINO-ACID DIFFERENCE FORMULA TO HELP EXPLAIN PROTEIN EVOLUTION
    GRANTHAM, R
    [J]. SCIENCE, 1974, 185 (4154) : 862 - 864
  • [10] Detailed computational study of p53 and p16:: using evolutionary sequence analysis and disease-associated mutations to predict the functional consequences of allelic variants
    Greenblatt, MS
    Beaudet, JG
    Gump, JR
    Godin, KS
    Trombley, L
    Koh, J
    Bond, JP
    [J]. ONCOGENE, 2003, 22 (08) : 1150 - 1163